Pfizer Breaks Ground for new Andover Clinical Manufacturing Facility

Pfizer Breaks Ground for new Andover Clinical Manufacturing Facility

Jul 29, 2016

Pfizer Inc. broke ground last month for its new biologics clinical manufacturing facility in Andover, Massachusetts. Expanding the company’s presence in the state, Pfizer will invest more than $200 million in development of the 175,000 sq. ft. state-of-the-art facility that will enable the production of high-quality, complex biologics and vaccines.

The Andover Clinical Manufacturing Facility will produce cGMP compliant clinical drug substances and will replace the current manufacturing facility in St. Louis. The new 5-story building is expected to be fully operational by January 2019, replacing all of the current St. Louis clinical manufacturing capability by the start of 2020.

“Pfizer’s decision to expand their campus in Andover speaks to the Commonwealth’s continued global leadership in biopharma and our administration’s support of the growing advanced manufacturing sector,” said Massachusetts Lieutenant Governor Karyn Polito. “We are pleased to have Pfizer operating in Andover, Boston, and Cambridge and look forward to their ongoing contributions to Massachusetts’s economy and wellbeing of our citizens.”

Senator Barbara L’Italien said. “This project is a testament to Pfizer’s commitment to Andover and I look forward to the facility opening in early 2019.”

CRB’s Jeff Biskup, Tim Greenwald, Tammi McAllister, and Jack Striebel represented the CRB team at the event. 

The new clinical manufacturing facility is designed with five independent manufacturing suites to support Pfizer’s highly complex and diverse biologics research effort. The facility will:

  • Employ flexible design to fully enable Next Generation Manufacturing strategies
  • Leverage state-of-the-art single-use bioreactors and disposable process technologies
  • Provide clinical manufacturing options with the lowest cost and greatest flexibility for efficiently driving important clinical drugs to patients

CRB is responsible for all architectural and engineering design and provided early pre-construction support to allow an aggressive start to construction. Starting with the concept design in September of 2015, the design and construction schedule was fast-tracked in order to break ground in April 2016 and have an enclosed building prior to that winter. Design firms OES and VHB are sub-contracted to CRB for structural and civil design activities respectively.

“The expansion of Pfizer’s presence in Andover will provide state-of-the-art manufacturing to help bring new medicines and vaccines to the patients we serve,” said John Ludwig, senior vice president, BioTherapeutics Pharmaceutical Sciences in Pfizer R&D. “Andover is a crucial part of our global footprint for both clinical and commercial manufacturing, and we believe it provides an attractive location for growth in the coming years.” 

shovel crbnet